Importer of Controlled Substances Application: Royal Emerald Pharmaceuticals Research and Development DBA: Royal Emerald Pharmaceuticals, 17642 [2021-06900]

Download as PDF 17642 Federal Register / Vol. 86, No. 63 / Monday, April 5, 2021 / Notices INTERNATIONAL TRADE COMMISSION [Investigation Nos. 701–TA–650–651 (Final)] Phosphate Fertilizers From Morocco and Russia jbell on DSKJLSW7X2PROD with NOTICES Determinations On the basis of the record 1 developed in the subject investigations, the United States International Trade Commission (‘‘Commission’’) determines, pursuant to the Tariff Act of 1930 (‘‘the Act’’), that an industry in the United States is materially injured by reason of imports of phosphate fertilizers from Morocco and Russia, provided for in subheadings 3103.11.00, 3103.19.00, 3103.90.00, 3105.10.00, 3105.20.00, 3105.30.00, 3105.40.00, 3105.51.00, 3105.59.00, 3105.60.00, and 3105.90.00 of the Harmonized Tariff Schedule of the United States, that have been found by the U.S. Department of Commerce (‘‘Commerce’’) to be subsidized by the governments of Morocco and Russia.2 3 Background The Commission instituted these investigations effective June 26, 2020, following receipt of petitions filed with the Commission and Commerce by The Mosaic Company, Plymouth, Minnesota. The Commission scheduled the final phase of the investigations following notification of preliminary determinations by Commerce that imports of phosphate fertilizers from Morocco and Russia were being subsidized within the meaning of section 703(b) of the Act (19 U.S.C. 1671b(b)). Notice of the scheduling of the final phase of the Commission’s investigations and of a public hearing to be held in connection therewith was given by posting copies of the notice in the Office of the Secretary, U.S. International Trade Commission, Washington, DC, and by publishing the notice in the Federal Register of December 8, 2020 (85 FR 79033). In light of the restrictions on access to the Commission building due to the COVID–19 pandemic, the Commission conducted its hearing through written testimony and video conference on February 9, 2021. All persons who requested the opportunity were permitted to participate. The Commission made these determinations pursuant to § 705(b) of the Act (19 U.S.C. 1671d(b)). It completed and filed its determinations 1 The record is defined in § 207.2(f) of the Commission’s Rules of Practice and Procedure (19 CFR 207.2(f)). 2 86 FR 9479 and 86 FR 9482 (February 16, 2021). 3 Commissioner Johanson dissenting. VerDate Sep<11>2014 17:23 Apr 02, 2021 Jkt 253001 in these investigations on March 31, 2021. The views of the Commission are contained in USITC Publication 5172 (March 2021), entitled Phosphate Fertilizers from Morocco and Russia: Investigation Nos. 701–TA–650–651 (Final). By order of the Commission. Issued: March 31, 2021. Lisa Barton, Secretary to the Commission. is notice that on May 22, 2020, Royal Emerald Pharmaceuticals Research and Development DBA: Royal Emerald Pharmaceuticals, 14011 Palm Drive, Desert Hot Springs, California 92240, applied to be registered as an importer of the following basic class(es) of controlled substance(s): Controlled substance [FR Doc. 2021–06955 Filed 4–2–21; 8:45 am] BILLING CODE 7020–02–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–810] Importer of Controlled Substances Application: Royal Emerald Pharmaceuticals Research and Development DBA: Royal Emerald Pharmaceuticals Drug Enforcement Administration, Justice. ACTION: Notice of application. Marihuana ....................... Tetrahydrocannabinols ... I Drug code Schedule 7360 7370 I I The company plans to import Marihuana seeds and immature Marihuana plants in the form of Active Pharmaceutical Ingredients (API) and botanical raw materials for DEAapproved legitimate scientific medical research and/or industrial purposes. William T. McDermott, Assistant Administrator. [FR Doc. 2021–06900 Filed 4–2–21; 8:45 am] BILLING CODE P AGENCY: DEPARTMENT OF JUSTICE Royal Emerald Pharmaceuticals Research and Development DBA: Royal Emerald Pharmaceuticals has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information. DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before May 5, 2021. Such persons may also file a written request for a hearing on the application on or before May 5, 2021. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All request for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this SUMMARY: PO 00000 Frm 00057 Fmt 4703 Sfmt 4703 Federal Bureau of Investigation Meeting of the Compact Council for the National Crime Prevention and Privacy Compact Federal Bureau of Investigation, Department of Justice. ACTION: Meeting notice. AGENCY: The purpose of this notice is to announce a meeting of the National Crime Prevention and Privacy Compact Council (Council) created by the National Crime Prevention and Privacy Compact Act of 1998 (Compact). DATES: The Council will meet virtually due to Covid–19 from 1:00 p.m. (EDT) until 6:00 p.m. (EDT) on May 12, 2021. ADDRESSES: Due to COVID–19 the meeting will be held virtually. The public will be permitted to provide comments and/or questions related to matters of the Council prior to the meeting, and participate in a listen-only mode upon prior registration. Please see details in the supplemental information. FOR FURTHER INFORMATION CONTACT: Inquiries may be addressed to Mrs. Chasity S. Anderson, FBI Compact Officer, Biometric Technology Center, 1000 Custer Hollow Road, Clarksburg, West Virginia 26306, telephone 304– 625–2803. SUPPLEMENTARY INFORMATION: Thus far, the Federal Government and 34 states are parties to the Compact which governs the exchange of criminal history records for licensing, employment, SUMMARY: E:\FR\FM\05APN1.SGM 05APN1

Agencies

[Federal Register Volume 86, Number 63 (Monday, April 5, 2021)]
[Notices]
[Page 17642]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-06900]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-810]


Importer of Controlled Substances Application: Royal Emerald 
Pharmaceuticals Research and Development DBA: Royal Emerald 
Pharmaceuticals

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

-----------------------------------------------------------------------

SUMMARY: Royal Emerald Pharmaceuticals Research and Development DBA: 
Royal Emerald Pharmaceuticals has applied to be registered as an 
importer of basic class(es) of controlled substance(s). Refer to 
Supplemental Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may file written comments on or objections to 
the issuance of the proposed registration on or before May 5, 2021. 
Such persons may also file a written request for a hearing on the 
application on or before May 5, 2021.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a 
hearing must be sent to: Drug Enforcement Administration, Attn: 
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All 
request for a hearing should also be sent to: (1) Drug Enforcement 
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, 
Springfield, Virginia 22152; and (2) Drug Enforcement Administration, 
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, 
Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this 
is notice that on May 22, 2020, Royal Emerald Pharmaceuticals Research 
and Development DBA: Royal Emerald Pharmaceuticals, 14011 Palm Drive, 
Desert Hot Springs, California 92240, applied to be registered as an 
importer of the following basic class(es) of controlled substance(s):

------------------------------------------------------------------------
                                          Drug
          Controlled substance            code           Schedule
------------------------------------------------------------------------
Marihuana..............................    7360  I
Tetrahydrocannabinols..................    7370  I
------------------------------------------------------------------------

    The company plans to import Marihuana seeds and immature Marihuana 
plants in the form of Active Pharmaceutical Ingredients (API) and 
botanical raw materials for DEA-approved legitimate scientific medical 
research and/or industrial purposes.

William T. McDermott,
Assistant Administrator.
[FR Doc. 2021-06900 Filed 4-2-21; 8:45 am]
BILLING CODE P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.